Real World Study on Oral Estradiol Treatment in Transgender Women

    October 2022 in “ Journal of the ASEAN Federation of Endocrine Societies ”
    Debmalya Sanyal, Anirban Mazumdar, Soumyabrata Roy Chaudhuri
    From the encyclopedia
    Spironolactone →

    powerful topical and oral anti-androgen used mostly by women

    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Estradiol →

    an estrogen promoting hair regrowth more commonly used in women

    Studysummary This study found that GnRH-a treatment or orchiectomy, which required significantly lower doses of oral estradiol valerate, were more effective than anti-androgens like spironolactone and finasteride in achieving target hormone levels in transgender females in India. Our plain-language summary of this paper — not a Tressless recommendation.
    This study evaluated the effectiveness of oral estradiol valerate (EV) in 103 transgender females (TGF) in India, divided into three groups: those using anti-androgens, post-orchiectomy, or GnRH-a. The study found that groups using GnRH-a or post-orchiectomy required significantly lower doses of EV and were more effective in achieving target hormone levels compared to those using anti-androgens. Specifically, 32% of the overall cohort achieved target estradiol levels, and 56% achieved target testosterone levels. Groups B and C had higher success rates in reaching these targets compared to group A. The study concluded that GnRH-a or orchiectomy is more effective than anti-androgens for hormone level management in TGF, and that spironolactone and finasteride were not effective in testosterone suppression.
    Discuss this study in the Community →